WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 15, 468-482. Review Article ISSN 2277–7105

ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL QUALITY ASSURANCE: APPLICATIONS, CHALLENGES AND FUTURE PERSPECTIVE

Jeel Modi*, Reetuben Patel, Khushbu Patel, Dr. C. N. Patel

Department of Pharmaceutical Quality Assurance, Shri Sarvajnik Pharmacy College, Near Arvind Baug, Mehsana, Gujarat, India.

Article Received on 27 June 2026,
Article Revised on 17 July 2026,
Article Published on 01 Aug. 2026,

https://doi.org/10.5281/zenodo.21674626

***Corresponding Author**

Jeel Modi

Department of Pharmaceutical Quality Assurance, Shri Sarvajnik Pharmacy College, Near, Arvind Baug, Mehsana, Gujarat, India.

How to cite this Article: Jeel Modi*, Reetuben Patel, Khushbu Patel, Dr C. N. Patel. (2026). Artificial Intelligence In Pharmaceutical Quality Assurance: Applications, Challenges And Future Perspective. World Journal of Pharmaceutical Research, 15(15), 468–482.

ABSTRACT

The pharmaceutical and healthcare industries have benefited significantly from advances in artificial intelligence in recent years. In the pharmaceutical sector, artificial intelligence (AI) has become a game-changing technology, especially in Quality Assurance (QA). Through advanced data analytics, machine learning (ML), deep learning (DL), natural language processing (NLP), and predictive modelling, AI-driven solutions enhance production productivity, product quality, automation, accuracy, regulatory compliance, and decision-making. Real-time monitoring, automated documentation, anomaly detection, predictive maintenance, and risk-based quality management are all made possible through the use of AI into pharmaceutical QA. Despite its benefits, implementation is still severely hampered by obstacles including data integrity, regulatory ambiguity, model validation, cybersecurity, and ethical dilemmas. These technologies lower human error and enhance product quality while supporting continuous manufacturing, Process Analytical Technology (PAT), and Quality by Design (QbD). This review discusses the applications, benefits, challenges, limitations, and future prospectives of AI in pharmaceutical Quality Assurance.

KEYWORDS: Artificial intelligence, Machine Learning, Pharmaceutical Quality Assurance, Process Analytical Technology, Regulatory compliance and data integrity.

INTRODUCTION

Introduction to Artificial Intelligence[1]

The fast developing discipline of computer science known as artificial intelligence (AI) focuses on creating computers and computer systems that are able to carry out activities that normally require human intellect. Learning from experience, thinking, problem-solving, decision-making, language comprehension, pattern identification, and visual perception are some of these skills. With little assistance from humans, AI enables computers to evaluate massive amounts of data, spot intricate patterns, and produce precise forecasts. John McCarthy initially used the phrase "Artificial Intelligence" in 1956 at the Dartmouth Conference, which signalled the start of AI as a recognised academic field. Since then, the capabilities and uses of AI have been greatly increased across a variety of industries, including healthcare and pharmaceuticals, thanks to developments in computer power, data availability, and algorithm development.

Artificial intelligence can be classified into[2]

Narrow AI (Weak AI) – This AI can perform specific tasks well, like facial recognition, driving cars, or playing chess, but it’s limited to those and lacks general human-like intelligence.

General AI (Strong AI) – General Artificial Intelligence is as smart as a human and can handle a wide range of tasks, learn from experience, and solve different problems, just like human do.

Super AI: Super Artificial Intelligence is even smarter than humans and can excel in areas like advanced mathematics, painting, and scientific research, going beyond human abilities. Building of an AI planner.

Key Technologies of AI

Machine Learning (ML)

Deep Learning (DL)

Natural Language Processing (NLP)

Computer Vision

Artificial Neural Network

Analytical Prediction

Robotics Process Automation

Together, these AI tools enable predictive decision-making, automate repetitive quality activities, detect process irregularities, and analyse massive amounts of pharmaceutical data. Their use into pharmaceutical quality systems increases productivity, reduces human error, and strengthens adherence to regulations.

Introduction to Quality Assurance (QA)[3,4]

Quality Assurance (QA) is a systematic and proactive approach that ensures products and services consistently meet predefined quality standards, regulatory requirements, and customer expectations. It encompasses all planned and organized activities implemented within a quality system to provide confidence that a product will satisfy quality requirements.

In the pharmaceutical industry, Quality Assurance plays a critical role in ensuring the safety, efficacy, and quality of medicines throughout their lifecycle, from raw material procurement to manufacturing, packaging, storage, and distribution. QA focuses on preventing defects rather than detecting them after production by establishing and monitoring robust processes, procedures, and documentation systems.

The risk-based methodology used in modern pharmaceutical quality assurance places a strong emphasis on data integrity, quality risk management, and continuous improvement throughout the course of a product's lifespan. By providing proactive quality management and real-time monitoring, the use of digital technologies, such as artificial intelligence, has significantly boosted QA systems.

Quality Assurance is closely associated with World Health Organization Good Manufacturing Practices (GMP), validation, quality audits, change control, deviation management, and corrective and preventive actions (CAPA). These activities help maintain compliance with regulatory standards and ensure consistent product quality.

The primary objectives of QA are

- To Ensuring product quality, safety, and efficacy.
- To Maintaining compliance with GMP and regulatory requirements.
- To Preventing errors and quality defects.
- To Promoting continuous process improvement.
- To Enhancing customer satisfaction and trust.
- To Ensuring accurate documentation and data integrity.

- To Minimizing product recalls and quality related risks.

With advances in technology, modern QA systems increasingly incorporate digital tools, automation, and Artificial Intelligence (AI) to improve efficiency, accuracy, and decision-making. Thus, Quality Assurance serves as the foundation of pharmaceutical quality systems and is essential for protecting patient health and ensuring regulatory compliance.

Integration of Artificial Intelligence in Quality Assurance[5,6]

The integration of artificial intelligence into pharmaceutical quality assurance has revolutionized quality management by providing real-time monitoring, predictive analytics, automated inspections, and intelligent decision-making, artificial intelligence's incorporation into pharmaceutical quality assurance has completely transformed quality management. Machine learning, deep learning, computer vision, and natural language processing are examples of AI technologies that help detect deviations, anticipate equipment breakdowns, streamline production procedures, and guarantee regulatory compliance.

Need for Artificial intelligence in Quality Assurance[3,6,7,8]

By facilitating more effective, precise, and proactive quality management across the product lifecycle, artificial intelligence (AI) is revolutionising pharmaceutical quality assurance. Conventional QA systems mostly rely on labour-intensive, human error-prone manual inspections, comprehensive documentation, and retrospective analysis. AI offers advanced analytical skills to spot patterns, spot abnormalities, and enable real-time process monitoring as pharmaceutical production grows more complicated and produces massive amounts of process and quality data. AI also supports compliance with FDA 21 CFR Part 11, GAMP 5, ICH guidelines by improving electronic records, audit trials, and documentation accuracy. Its incorporation into quality systems improves data integrity and traceability while bolstering risk management, deviation handling, corrective and preventative actions (CAPA), document management, audit management, change control, and regulatory compliance. Additionally, AI makes it easier to identify any quality problems early on, enabling prompt remedial action before product quality is compromised. Additionally, by facilitating intelligent, predictive, and data-driven decision-making, AI increases operational efficiency, lowers manufacturing costs, promotes continuous improvement, and improves patient safety. AI is becoming a crucial technology for creating strong, dependable, and future-ready pharmaceutical quality assurance systems thanks to the development of digital transformation and Pharma 4.0.

AI Technologies used in Pharmaceutical Quality



Figure 1: Techniques of AI.

Machine learning (ML)[10,11]

Machine learning is a branch of AI that makes use of statistical methods to enable machines to get better over time. ML algorithms generate predictions or choices based on fresh inputs after identifying patterns in past data. This is very helpful in anticipating quality flaws or process variations before they happen. Typical ML types in QA:

1. Supervised Learning: Labelled data (such as defect or no defect) is used to teach algorithms.
2. Unsupervised Learning: Algorithms identify patterns (such as grouping anomalies) in unlabelled data.
3. Reinforcement Learning: Through trial and error and feedback, systems (like adaptive process control) discover the best course of action.

Deep learning (DL)[12,13]

A branch of machine learning called "Deep Learning" makes use of multi-layered artificial neural networks. Applications consist of:

Analysing complex data

Finding flaws in pharmaceutical goods

Recognising patterns and images

Predicting quality throughout production

DL models are used in computer vision for visual inspection and in natural language processing for document analysis.

Computer Vision[14]

Machines are able to analyse and evaluate visual data from pictures, videos & movies due to computer vision. It is employed in QA for:

Automated visual analysis of packaging, pills, and capsules

Crack, discolouration, and contaminant detection

Checks for packing integrity and label verification

Defects detection Measurement and Inspection Monitoring Production Processes

Natural Language Processing (NLP)[15,16]

NLP makes it possible for computers to comprehend and analyse human language. Application consist of:

Examination of SOPs and quality documentation

Monitoring of regulatory compliance

Automated creation of reports

Examining batch production documentation

Artificial Neural Networks (ANNs)[17]

By converting therapeutic compounds with less-than-ideal characteristics into efficient dosage forms, pharmaceutical technology enhances them. This process necessitates a thorough comprehension of physicochemical qualities and formulation factors. This is made possible by machine learning (ML), particularly deep learning/ANNs, which simulate intricate, nonlinear interactions between formulation components and process parameters without the need for presumptions.

In contrast to conventional machine learning, deep learning adjusts to complex systems where it is challenging to set clear rules (such as differentiating between crystalline and amorphous forms). ANNs may connect critical quality attributes (COAs) with critical material attributes (CMAs) and critical process parameters (CPPs) within the Quality by Design (QD) framework, allowing for formulation and process optimisation, sensitivity analysis, and predictive modelling.

ANNs are useful for creating multi-drug or controlled-release formulations, optimising tablet characteristics, and modelling unit operations. ANNs can optimise composition and process parameters to attain desired size, stability, and targeting efficiency in emerging applications creating nanocarriers such cerasomes.

Analytical Prediction[18,19]

AI and statistical methods are used in predictive analytics to predict future results. Applications consist of:

Predicting equipment failures

Expecting flaws in quality

An examination of manufacturing process trends

Cutting down on batch errors

AI-powered Robotic Process Automation (RPA)[20,21,22,23]

When paired with AI, RPA may automate repetitive processes and:

Automate the examination of documents

Keep track of quality records.

Produce reports on compliance

Boost the effectiveness of your workflow

Virtual copies of actual manufacturing systems are called digital twins. They have been used to:

- Replicate manufacturing procedures
- Track the quality of the goods in real time
- Enhance production processes
- Determine any dangers to quality before they arise.

Applications of AI in Quality Assurance (QA)[24,25,26,27,28]

1. **Automated Data Review and Analysis**

- Rapid analysis of large manufacturing and lab data.
- Detects trends, anomalies, and deviations missed by manual review.
- Reduces human errors in batch record reviews.

2. **Predictive Quality Management**

- Uses historical data to predict quality issues before occurrence.

- Prevents batch failures and product recalls.
- Supports proactive risk management.

3. Deviation and CAPA Management

- Identifies root causes of deviations.
- Suggests corrective and preventive actions.
- Improves investigation efficiency and compliance.

4. Document Management and Compliance

- Automates review of SOPs, validation, and regulatory documents.
- Ensures GMP compliance and reduces documentation workload.

5. Process Monitoring and Control

- Real-time monitoring of manufacturing processes.
- Detects process variations and alerts operators promptly.
- Enhances product quality and process reliability.

6. Risk Assessment

- Evaluates risks using historical quality data.
- Supports Quality Risk Management (QRM).
- Prioritizes critical quality issues.

7. Audit and Inspection Readiness

- Identifies compliance gaps pre-inspection.
- Facilitates internal audits and regulatory preparation.
- Improves overall compliance.

8. Visual Inspection

- AI computer vision inspects products and packaging.
- Detects defects like cracks, discoloration, contamination, and labelling errors.
- Offers faster, more accurate inspection than manual methods.
- Detect the impurities in production process.
- Ensure high quality products

9. Supplier Quality Management

- Evaluates supplier performance and supply chain risks.
- Assists in vendor qualification and monitoring.
- Enhances raw material quality assurance.

10. Continuous Improvement

- Identifies process optimization opportunities.
- Supports data-driven decision-making.
- Strengthens overall quality culture.

11. Anomaly Detection

- AI uses advanced algorithms to identify deviations or unusual pattens in manufacturing processes
- Enabling early intervention to prevent defects and maintain product quality

12. Environmental Monitoring

- AI analyze environmental monitoring data from cleanrooms, HVAC systems, and water system to identify unusual patterns before they have an impact on product quality.
- Predictive alarms lower the risk of contamination and assist maintain regulated industrial settings.

Challenges of AI in QA[29,30]

1. Data Quality and Availability

Large amounts of precise, comprehensive, and representative data are necessary for artificial intelligence to generate dependable outcomes. Data from production procedures, laboratory testing, equipment monitoring, and quality management systems are gathered for pharmaceutical quality assurance. AI algorithms may produce incorrect quality decisions and erroneous forecasts if these datasets have bias, errors, missing values, or inconsistencies. For AI to be implemented successfully, high-quality, standardized, and carefully selected data must be maintained. In order to provide trustworthy, traceable, and legally compliant pharmaceutical data throughout the product lifecycle, AI systems should also adhere to the ALCOA+ principles of data integrity (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available).

2. Validation of AI Models

AI systems, in contrast to traditional software, are constantly learning from data and may undergo performance changes over time. Because the model must continuously exhibit accuracy, robustness, repeatability, and dependability throughout its existence, validation becomes more difficult. Regulators anticipate that AI models employed in pharmaceutical quality systems will be adequately validated before to deployment and continuously monitored following implementation.

3. Regulatory Compliance

The pharmaceutical sector is governed by stringent regulations such as Good Manufacturing Practices (GMP), Good Automated Manufacturing Practice (GAMP 5), 21 CFR Part 11, and ICH quality requirements. While ensuring patient safety, electronic records, audit trails, and data integrity, AI systems must abide by these regulations. Because AI rules are still being developed, organisations are unsure about regulatory acceptability and compliance needs.

4. Lack of Transparency and Explainability

Many sophisticated AI models, especially deep learning algorithms, operate as "black-box" systems as they produce predictions without providing a clear justification. Decisions in pharmaceutical quality assurance must be transparent and supported by science, according to regulators and quality experts. Limited explainability makes regulatory clearance more difficult and lowers confidence in AI-generated suggestions. To overcome this obstacle, Explainable Artificial Intelligence (XAI) has been developed.

5. Integration with Existing Systems

Enterprise Resource Planning (ERP), Manufacturing Execution Systems (MES), Laboratory Information Management Systems (LIMS), and Quality Management Systems (QMS) are used by the majority of pharmaceutical organisations. It takes a great deal of technical knowledge, software changes, and infrastructure improvements to integrate AI with these old systems. Adoption of AI may be delayed by compatibility problems and implementation difficulty.

6. Data Privacy and Cybersecurity

Large volumes of private industrial, laboratory, and quality-related data are processed by AI systems. Sensitive information may be compromised and regulatory compliance may be impacted by unauthorised access, cyberattacks, or data breaches. Therefore, in order to

safeguard AI systems, organisations need to put in place robust cybersecurity measures, encryption, access restrictions, and data governance regulations.

7. High Implementation Cost

AI implementation necessitates significant investments in data storage, cloud infrastructure, technology, software, qualified staff, and employee training. Operational expenses are further raised by regular maintenance, software upgrades, model retraining, and cybersecurity precautions. Adoption of AI may be constrained by these budgetary constraints, especially in small and medium-sized pharmaceutical businesses.

8. Shortage of Skilled Professionals

Multidisciplinary knowledge of artificial intelligence, machine learning, pharmaceutical sciences, quality assurance, statistics, and regulatory affairs is necessary for the effective use of AI. However, a lack of experts with these combined abilities is a problem for many pharmaceutical companies, making AI deployment and maintenance more difficult.

9. Continuous Monitoring and Model Maintenance

AI models are dynamic. Model accuracy may gradually decline due to modifications in production settings, raw materials, machinery, or manufacturing methods (model drift). Therefore, to maintain constant performance throughout their existence, AI systems need regular revalidation, periodic retraining using new datasets, and ongoing performance monitoring.

10. Ethical and Legal Concerns

The use of AI brings up moral questions about responsibility for assessments regarding quality, accountability, justice, and transparency. Determining legal culpability might be challenging if an AI system produces a forecast that is inaccurate and compromises patient safety or product quality. To guarantee the ethical and responsible use of AI, organisations must maintain human supervision and set up explicit governance structures.

11. Resistance to Organizational Change

As AI is introduced, job duties and workflows are frequently altered. Workers may be reluctant to embrace AI because they fear losing their jobs, don't trust automated technologies, or haven't received enough training. Effective change management, education, and ongoing training are necessary for successful implementation in order to foster

acceptance and foster trust.

12. Dependence on Human Oversight

AI increases productivity and decision-making, but it cannot take the position of skilled, seasoned experts. Reviewing AI-generated outputs, looking into deviations, approving crucial quality choices, and ensuring regulatory compliance still require human specialists. AI should not be seen as a substitute for human knowledge, but rather as a tool for decision-making.

FUTURE PERSPECTIVES[3,4,31,32]

It is expected that artificial intelligence (AI) would revolutionise pharmaceutical quality assurance (QA) by increasing the predictability, efficiency, and data-driven approach of quality management. In order to provide real-time production process monitoring and early identification of quality violations, AI will eventually be extensively integrated with Industry 4.0 technologies including the Internet of Things (IoT), big data analytics, cloud computing, and digital twins. Predictive quality management, automated deviation investigations, risk assessment, CAPA management, and real-time release testing (RTRT) will all be supported by AI, which will lower human error and enhance product quality. By offering concise justifications for judgements made by AI, Explainable AI (XAI) is anticipated to boost transparency and regulatory acceptability. Quality Management Systems (QMS) driven by AI will increase operational efficiency by automating document review, audit preparation, and compliance monitoring. AI will also improve manufacturing procedures, strengthen supplier quality control, and facilitate the manufacture of personalised medicines. AI has the potential to become a crucial component of pharmaceutical quality assurance (QA) as regulatory frameworks change and AI validation techniques become more standardised. This will improve product quality, increase regulatory compliance, lower costs, and improve patient safety.

CONCLUSION

By increasing productivity, accuracy, product quality, and regulatory compliance, artificial intelligence has become a game-changing tool in pharmaceutical quality assurance. Predictive analytics, real-time monitoring, automated documentation, anomaly detection, and risk-based decision-making are made possible by artificial intelligence (AI) technologies, such as machine learning, deep learning, natural language processing, computer vision, and robotic process automation. These features support the pharmaceutical industry's efforts to reduce human error, improve production procedures, bolster data integrity, and guarantee

constant product quality. The use of AI is anticipated to be accelerated by ongoing technology developments and supporting regulatory frameworks, despite obstacles including data quality, cybersecurity, model validation, ethical issues, and changing regulatory requirements. AI will be essential in creating more intelligent, dependable, and patient-focused quality systems as the pharmaceutical sector moves toward digital transformation and Pharma 4.0. All things considered, the effective incorporation of AI into quality assurance has the ability to increase patient safety, assure regulatory compliance, and boost operational excellence while influencing the direction of pharmaceutical manufacture.

REFERENCES

1. Russell SJ, Norvig P. *Artificial Intelligence: A Modern Approach.* 4th ed. Pearson, 2021.
2. Inamdar S, Kedar T, Gujar H, Tanpure P, Sapkal S. Harnessing AI and Machine Learning in Pharmaceutical Quality Assurance. *Int J Sci Res Tech.*, 2024; 1(11): 145-150.
3. International Council for Harmonisation (ICH). *ICH Q10: Pharmaceutical Quality System.*Geneva: ICH, 2008.
4. International Council for Harmonisation (ICH). *ICH Q9(R1): Quality Risk Management.* Geneva: ICH, 2023.
5. Makhane S., Borade B., Dighade S.J. *Impact of Artificial Intelligence on Improving Pharmaceutical Quality Assurance Systems.* IJPS Journal, 2025.
6. Paul D, Sanap g, Shenoy S, et al. Artificial intelligence in drug Discovery today, 2021; 26(1): 80-93.
7. International Society for Pharmaceutical Engineering (ISPE). *Pharma 4.0^{TM}* Operating Model. ISPE, 2021.
8. U.S. Food and Drug Administration. 21CFR Part 11: Electronic Records; Validation-General Principles and Practices. Silver Spring (MD): FDA, 2011.
9. United States Food and Drug Administration. *Guidance for Industry: Process Validation-General Principles and Practices.* FDA, 2011.
10. Mak kk, Pichika MR. Artificial intelligence in drug development: Present status and future prospects. *Drug Discovery Today*, 2019; 24(3): 773-780.
11. Deshmukh D., Datkhile S., Gosavi O., et al. *Artificial Intelligence and Machine Learning in Pharmaceutical Quality Assurance.* International Journal of Pharmaceutical Sciences (IJPS), 2024.
12. Goodfellow I, Bengio Y, Courville A. *Deep Learning*. MIT Press, 2016.

13. LeCun, Y., Bengio, Y., & Hinton, G. (2015). Deep Learning. *Nature*, 521(7553): 436-444.
14. Sarker, I.H. AI-Based Computer Vision Techniques in Industry 4.0 Manufacturing. *Journal of Big Data*, 2022; 9: 1-31.
15. Jurafsky, D., & Martin, J.H. (2023). Speech and Language Processing (3rd ed., draft). Pearson.
16. Savova, G. K., et al. Mayo Clinical Text Analysis and Knowledge Extraction System (cTAKES) Architecture, Component Evaluation and Applications. *Journal of the American Medical Informatics Association*, 2010; 17(5): 507-513.
17. Teja, T. E., Sekar, M., Pallavi, T., Mettu, s., Murthy, T.E., Mat Rani, N. N. I., …& Bonam, S.R. Role of Artificial Neural Networks in Pharmaceutical Science. Journal of Young Pharmacists, 2022; 14(1).
18. Witten, I. H., Frank, E., Hall, M. A., & Pal, C. J. (2016). *Data Mining: Practical Machine Learning Tools and Techniques* (4th ed.). Morgan Kaufmann.
19. Kourentzes, N., et al. (2020). Predictive Analytics in Manufacturing: A Review. *International Journal of Production Economics.*
20. Aguirre, S., & Rodriguez, A. Automation of a Business Process USING Robotic Process Automation (RPA): A Case Study. *Lecture Notes in Computer Science*, 2017; 10570: 65-71.
21. Lacity, M., & Willcocks, L. (2018). *Robotic Process Automation and Risk Mitigation*. SB Publishing.
22. Tao, F., Zhang, H., Liu, A., & Nee, A. Y. C. Digital Twin in Industry: State-of-the-Art. *IEEE Transactions on Industrial Informatics*, 2019; 15(4): 2405-2415.
23. Fuller, A., Fan, Z., Day, C., & Barlow, C. Digital Twin: Enabling Technologies, Challenges and Open Research. *IEEE* Access, 2020; 8: 108952-108971.
24. International Society for Pharmaceutical Engineering (ISPE). (2023). *Artificial Intelligence and Machine Learning (AI/ML) in Pharmaceutical Manufacturing.* ISPE.
25. Veillon R., Shabushnig J., Aabye-Hansen L., et al. "Applying Machine Learning to the Visual Inspection of Filled Injectable Drug Products." *PDA Journal of Pharmaceutical Science and Technology*, 2023; 77(5): 376-401.
26. AI for QA. "AI for Supplier Quality Management in Pharmaceuticals."
27. Nakka, G., Gupta, S., & Reddy, K. K. *Artificial intelligence in pharmaceutical manufacturing: Application, case studies, and GxP implementation considerations.* Journal of Pharmaceutical Sciences, 2026; 115(5): 104240.

28. Saha, G. C., Eni, L. N., Saha, H., Parida, P. K., Rathinavelu, R., Jain, S.k., & Haldar, B. Artificial Intelligence in pharmaceutical Manufacturing: Enhancing quality control and decision making. Rivista Italiana di Filosofia Analitica Junioe, 2023; 14(2): 2023.
29. ISPE (2020) Pharma 4.0 Operating Model. International Society for Pharmaceutical Engineering.
30. Mintanciyan A, Budihandojo R, English J, Lopez O, Matos J, McDowall R. *Artificial Intelligence Governance in GxP Environments.* Pharmaceutical Engineering, 2024; 44(4). International Society for Pharmaceutical Engineering (ISPE).
31. European Medicines Agency. Reflection Paper on the *Use of Artificial Intelligence in the Medicinal Product Lifecycle*, 2023.
32. World Health Organization. *Ethics and Governance of Artificial Intelligence for Health: WHO Guidance.* Geneva: World Health Organization, 2021.